

Age-Related Macular Degeneration

An Observational Study of the Progression of Intermediate Age-Related Macular Degeneration

Trial Status
Recruiting

Trial Runs In
7 Countries

Trial Identifier
NCT05300724 2022-000046-15
GE43220

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This is a multicenter prospective study in participants with intermediate age-related macular degeneration (iAMD). One primary objective of this study is to assess iAMD disease progression, by the timeline and rates of conversion for high-risk iAMD at baseline to more advanced atrophic AMD stages. The other primary objective of this observational study is to assess the feasibility of measuring the rate of photoreceptor loss as a potential clinical endpoint. The study will consist of an observation period of approximately 3 years (~144 weeks) for participants.

Genentech, Inc.
Sponsor

NCT05300724 2022-000046-15 GE43220
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
≥50 Years & ≤ 94 Years

Healthy Volunteers
No
